• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Rheumatology

Show Search
Hide Search
  • About Us
    • Our History
    • Our Faculty
    • Rheumatology Fellowship
    • Administrative Core
    • Contact Us
    • eNews Signup
  • Make an Appointment
    • Clinic Information
    • Specialty Clinics
  • Our Research
    • Current Research Studies
    • Andrade Lab
    • Antiochos Lab
    • Casciola-Rosen Lab
    • Darrah Lab
    • Konig Lab
    • RDRCC
    • Bayview Immunomics Core (BIC)
  • Charitable Giving
    • Dr. John Welton Fellowship in Rheumatology
    • Dr. Ira T. Fine Discovery Fund
    • Dr. Nadia D. Morgan Memorial Fund
  • News
    • LEAP Magazine
  • Education
    • Advances in the Diagnosis and Treatment of the Rheumatic Diseases Course
    • RheumTV – Patient Education Video Library
Home / News / Research / Muscle involvement more pronounced in dermatomyositis patients with anti-Mi2 antibodies

Muscle involvement more pronounced in dermatomyositis patients with anti-Mi2 antibodies

March 2, 2020 By Ashley Curran

Summary

Dermatomyositis (DM) is an autoimmune disease characterized by skeletal muscle weakness, skin rashes, and the presence of autoantibodies in the blood. These autoantibodies help clinicians diagnose and treat patients by defining unique patient subsets with different clinical symptoms and treatment responses. This study by researchers at Johns Hopkins and the NIH sought to define the clinical features of patients with Mi2 antibodies and investigate how these features evolve over time. Patients with anti-Mi2 positive DM had more severe muscle disease, characterized by muscle weakness and increased creatine kinase (CK) levels, which is a marker of muscle damage. Nearly all dermatomyositis patients with Mi2 autoantibodies experienced muscle weakness throughout the duration of their follow-up. However, most patients with anti-Mi2 antibodies had improved strength and CK levels after treatment.

Why was this study done?

Myositis-specific autoantibodies (MSAs) are protein markers in the blood that physicians use to help diagnose and treat patients with different types of muscle diseases, such as dermatomyositis. Understanding the clinical signs and symptoms associated with each antibody can be helpful in disease monitoring and prognosis. The study team therefore sought to characterize the clinical features associated with anti-Mi2 antibodies in DM over time.

How was this study done?

Researchers studied a total of 58 patients with Mi2-positive DM from the Johns Hopkins Myositis Cohort. In addition, patients with other types of myositis were included for comparison — 143 patients with Mi2-negative DM, 162 patients with anti-synthetase syndrome, and 170 patients with immune-mediated necrotizing myopathy. Each patient’s chart was reviewed for symptoms they experienced over time, and their disease characteristics (muscle biopsy characteristics, CK levels, etc.) were compared to those of other myositis types.

What were the major findings?

The majority of DM patients with Mi2 antibodies experienced weakness over their disease course but improved with treatment. Compared to patients with other types of DM, those with Mi2 antibodies were found to have higher CK levels and more muscle weakness, indicating more severe muscle disease. Among 10 patients with multiple blood samples collected over 4 or more years, the level of Mi2 autoantibodies decreased in all patients and normalized in three – two of whom stopped immunosuppressant treatment and never relapsed. Further, despite their more severe muscle involvement, patients with Mi2-positive DM had less calcinosis (i.e., accumulation of calcium deposits under the skin), interstitial lung disease, and fever than patients with Mi2-negative DM.

What is the impact of this work?

This study improves our understanding of myositis patients with Mi2 autoantibodies, which may assist clinicians in diagnosing and treating this subset of patients. The study team observed important clinical features that are associated with Mi2 antibodies, confirming their clinical value and their importance in disease diagnosis, monitoring, and prognosis.

This research was supported by:

  • The Jerome L. Greene Foundation

Publication Information

More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies. Pinal-Fernandez I, Mecoli CA, Casal-Dominguez M, Pak K, Hosono Y, Huapaya J, Huang W, Albayda J, Tiniakou E, Paik JJ, Johnson C, Danoff SK, Corse AM, Christopher-Stine L, Mammen AL. Neurology Nov 2019, 93 (19) e1768-e1777.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Filed Under: Research Tagged With: Dermatomyositis

Ashley Curran

Ashley Curran is a PhD candidate in the Johns Hopkins University Division of Rheumatology studying the mechanisms by which autoimmune responses develop in rheumatoid arthritis.

Use of this Site

All information contained within the Johns Hopkins Division of Rheumatology website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Rheumatology News

  • News
  • Promotions

Recent News

LEAP Winter 2025: Fighting Fire with Fire

February 27, 2025

LEAP Winter 2024: At the Cusp of Breakthroughs

February 23, 2024

LEAP – Winter 2023: Big Data, Individualized Care

February 23, 2024

RheumTV Logo

Rheum.TV is an educational platform created to help patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit RheumTV

Footer

Rheumatology Specialty Care Centers

  • Johns Hopkins Arthritis Center
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect with Us

  • Facebook
  • Twitter
  • YouTube
U.S. News and World Report Rankings Badge

Johns Hopkins Medicine

© 2025 Johns Hopkins Rheumatology - Patient Privacy